Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Brief Summary: This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.


Options:
A: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
B: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg
C: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
D: Arm Label: A1: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm A2: Capecitabine Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Arm A3: MEDI4736 (Durvalumab); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 (Durvalumab) | Arm Label: Arm B1: Trastuzumab Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab | Arm Label: Arm A4: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Arm A5: Capecitabine and Ramucirumab; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Ramucirumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A2: Capecitabine Maintenance, Arm A5: Capecitabine and Ramucirumab | Intervention Type: DRUG; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Arm A3: MEDI4736 (Durvalumab) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm B1: Trastuzumab Maintenance | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Arm A4: Rucaparib | Intervention Type: DRUG; Name: Ramucirumab; Assigned to Arm(s): Arm A5: Capecitabine and Ramucirumab

Answer: A